Meprobamate(me proe ba’ mate)
Novo-Mepro (CAN)
PREGNANCY CATEGORY D
CONTROLLED SUBSTANCE C-IV
Drug class
Anxiolytic
Therapeutic Actions
Has effects at many sites in the CNS, including the thalamus and limbic system; inhibits multineuronal spinal reflexes; is mildly tranquilizing; has some antiepileptic and central skeletal muscle relaxing properties.
Indications
Management of anxiety disorders for the short-term relief of the symptoms of anxiety (anxiety or tension associated with the stress of everyday life usually does not require treatment with anxiolytic drugs); effectiveness for longer than 4 mo not established.
Contraindications and Cautions
Contraindicated with hypersensitivity to meprobamate or to related drugs, such as carisoprodol; acute intermittent porphyria; hepatic or renal impairment; pregnancy; lactation.
Use cautiously with epilepsy (drug may precipitate seizures), depression, history of drug abuse.
Available Forms
Tablets—200, 400 mg
Dosages
Adults
1,200–1,600 mg/day PO in three or four divided doses. Do not exceed 2,400 mg/day.
Pediatric patients 6–12 yr
100–200 mg PO bid–tid.
Pediatric patients younger than 6 yr
Safety and efficacy not established.
Geriatric patients
Use lowest effective dose to avoid oversedation.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
